BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects
Phase 1
Completed
- Conditions
- Anemia
- Interventions
- Drug: BAY85-3934
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 56
- Registration Number
- NCT01318551
Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT01318265
BAY81-8973 Pediatric Safety and Efficacy Trial
Phase 3
Completed
- Conditions
- Haemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 94
- Registration Number
- NCT01311648
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
Phase 2
Completed
- Conditions
- Hypertension, Essential
- Interventions
- Drug: Nifedipine GITS (Adalat, BAYA1040), 20 mgDrug: Nifedipine GITS (Adalat, BAYA1040), 60 mgDrug: Candesartan cilexetil (Atacand), 4 mgDrug: Candesartan cilexetil (Atacand), 8 mgDrug: Nifedipine GITS (Adalat, BAYA1040), 30 mgDrug: PlaceboDrug: Candesartan cilexetil (Atacand), 16 mgDrug: Candesartan cilexetil (Atacand), 32 mg
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1381
- Registration Number
- NCT01303783
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- Drug: BAY87-2243
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5
- Registration Number
- NCT01297530
Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)
Phase 4
Completed
- Conditions
- Uterine Hemorrhage
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 187
- Registration Number
- NCT01295294
High Dose BAYA1040_Nifedipine: a Long Term Combination Study
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT01294215
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT01289821
High Dose BAYA1040_Nifedipine: a Dose-comparative Study
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 352
- Registration Number
- NCT01287260
BAY73-4506 Probe Substrate Study
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 41
- Registration Number
- NCT01287598
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada
© Copyright 2025. All Rights Reserved by MedPath